Conclusion
A comparative study of the fasting and postprandial plasma
pharmacokinetics of nifedipine extended-release tablets demonstrated the
bioequivalence of nifedipine extended-release tablets (Hunan Dino
Pharmaceutical Co., Ltd.) and the reference formulation, nifedipine
controlled-release tablets (trade name: Baysinto®, size: 30 mg/tablet
Bayer AG). Both drugs had a good safety profile, with no serious adverse
reactions occurring throughout the study period. Notably, the high-fat
diet reduced the AUC curve area by approximately 4.8%, with little
change in Cmax but an almost twofold advance in
Tmax.